Neupro use extended

The licence for Neupro (rotigotine) transdermal patch has been extended to include use as an adjuvant to levodopa therapy for advanced Parkinson's disease.

Neupro can be used in combination with levodopa over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).

A single daily dose should be initiated at 4mg/24h and then increased in weekly increments of 2mg/24h to an effective dose up to a maximum of 16mg/24h. For most patients an effective dose is reached within three to seven weeks. Neupro was launched in April 2006 for the treatment (as monotherapy) of early idiopathic Parkinson's disease signs and symptoms.

Further information: Schwarz Pharma 01923 684100
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more